Jeffrey A. Medin
Affiliations: | Medical Biophysics | University of Toronto, Toronto, ON, Canada |
Area:
Molecular Biology, ImmunologyGoogle:
"Jeffrey Medin"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wang X, McKillop WM, Dlugi TA, et al. (2023) A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice. The Journal of Gene Medicine. e3567 |
| Nagree MS, Felizardo TC, Faber ML, et al. (2022) Autologous, lentivirus-modified, T-rapa cell "micropharmacies" for lysosomal storage disorders. Embo Molecular Medicine. e14297 |
| Domm JM, Wootton SK, Medin JA, et al. (2021) Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing. Molecular Genetics and Metabolism |
| Oldham RAA, Faber ML, Keppel TR, et al. (2020) Discovery and validation of surface -glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets. Journal For Immunotherapy of Cancer. 8 |
| Li Y, Xu Y, Benitez BA, et al. (2019) Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target. Proceedings of the National Academy of Sciences of the United States of America |
| Yu FPS, Molino S, Sikora J, et al. (2019) Hepatic pathology and altered gene transcription in a murine model of acid ceramidase deficiency. Laboratory Investigation; a Journal of Technical Methods and Pathology |
| Nagree MS, Scalia S, McKillop WM, et al. (2019) An update on gene therapy for lysosomal storage disorders. Expert Opinion On Biological Therapy. 1-16 |
| Liu M, Juvet SC, Medin JA, et al. (2019) Lentiviral interleukin-10 gene therapy: Safety and questions. The Journal of Thoracic and Cardiovascular Surgery. 157: 818-819 |
| Neschadim A, Medin JA. (2019) Engineered Thymidine-Active Deoxycytidine Kinase for Bystander Killing of Malignant Cells. Methods in Molecular Biology (Clifton, N.J.). 1895: 149-163 |
| Nagree MS, Felizardo TC, Huang J, et al. (2019) Lentiviral-modified T Rapa cells as 'micropharmacies' for lysosomal diseases Molecular Genetics and Metabolism. 126: S105 |